**Poster Session A**  
**Friday, March 2, 2018**  
4:30 p.m. – 7:00 p.m.  
Grand Ballroom DEF

**A01, PR14**  
Reprogramming of DNA and histone methylome by cancer-associated histone H3 mutations.  
Chao Lu, Columbia University, New York, New York.

**A02**  
Delineating differential transcriptional roles for the ZBTB family of methyl-CpG binding proteins in cancer. Bethany Buck-Koehntop, University of Utah, Salt Lake City, UT.

**A03, PR01**  
DNA and histone methyltransferase inhibitors cooperate to increase viral mimicry in cancer cells. Minmin Liu, Van Andel Research Institute, Grand Rapids, Michigan.

**A04**  
UHRF1 depletion and HDAC inhibition synergistically reactivate epigenetically silenced genes in colorectal cancer cells. Hiromu Suzuki, Sapporo Medical University, Sapporo, Hokkaido, Japan.

**A05, PR02**  
Investigating the mechanisms by which ZBTB38 recognizes methylated DNA and modulates transcription. Nicholas Hudson, University of Utah, Salt Lake City, Utah.

**A07, PR03**  
Mismatch repair proteins initiate epigenetic alterations during inflammation-driven tumorigenesis. Heather O'Hagan, Indiana University School of Medicine, Bloomington, IN.

**A08**  
Epigenetic characterization of cancer-associated fibroblasts: Implication for epigenetic reprogramming therapy. Masahiro Maeda, Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.

**A09**  
Epigenome and transcriptome analyses by Methyl-seq and RNA-seq on the protective effects of ursolic Acid against UVB-irradiated inflammation in Nrf2 knockout and wild-type C57BL/6J Mice. Yuqing (Anne) Yang, Rutgers University, Piscataway, NJ.

**A10, PR07**  
Synthetic lethal targeting of TET2 loss in myeloid malignancies by TOP1 inhibitors. Chang-Bin Jing, Dana-Farber Cancer Institute, Boston, MA.

**A11**  
Loss of hydroxymethylcytosine is an independent adverse prognostic factor in clear cell Renal Cell Carcinoma (ccRCC) and can be abrogated by Ascorbic acid mediated TET activation. Niraj Shenoy, Mayo Clinic Rochester, Rochester, MN.

**A12, PR05**  
Genome-wide 5-hydroxymethylcytosine alterations in medulloblastoma. Hyerim Kim, Emory University, Atlanta, Georgia.

**A13**  
Mutational cooperativity of TET2 in peripheral T cell lymphoma. Yun Huang, Texas A&M University, Houston, TX.

**A14, PR08**  
Identification of specific readers of epigenetic modifications in human bronchial epithelial cells using a quantitative proteomics approach. Jenna Fernandez, Masonic Cancer Center, Minneapolis, MN.

**A16**  
Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum-refractory germ cell tumors (GCT): a phase 1 study. Costantine Albany, Indiana University, Indianapolis, IN.
A17 Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor SGI-110 in Hepatocellular Carcinoma Cells. Gangning Liang, Norris Comprehensive Cancer Center, Los Angeles, California.

A18 Rigosertib (RIG) Alone or in Combination with Azacitidine or Vorinostat has chromatin modifying effects and Epigenetically Reprograms Hematopoietic stem and progenitor cells in the Myelodysplastic Syndrome. Lewis Silverman, Icahn School of Medicine, New York, New York.

A19, PR06 Relapsing and refractory acute myeloid leukemia patients reveal converging genetic and epigenetic features suggesting common treatment strategies and response biomarkers. Timothy Triche, VARI, Grand Rapids, MI.

A20 Profiling breast cancer for decitabine response indicators reveals deoxycytidine kinase as key determinant of sensitivity. Margaret Thomas, Dalhousie University, Halifax, NS, Canada.

A21 Decitabine as a new therapeutic agent for T-cell acute lymphoblastic leukemia. Morgan Thénoz, Center for Medical Genetics (CMGG), Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

A22 Preclinical study of epigenetic drug-based differentiation therapy for neuroblastoma. Naoko Hattori, National Cancer Center Research Institute, Tokyo, Japan.

A23 A phase I trial of the epigenetic regulators, oral 5-azacitidine and romidepsin, for the treatment of advanced solid tumors, with a focus on virally mediated cancers and liposarcoma. Stephanie Gaillard, Johns Hopkins School of Medicine, Baltimore, MD.

A24 Development of gene regulation pyrrole-imidazole polyamides targeting the epigenetic deregulation biomarkers in oral squamous cell carcinoma. TZE-TA HUANG, Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan.


A26 DNA methylation signatures associated with pituitary macroadenomas functional status. Maritza Mosella, Henry Ford Health System, Detroit, MI.

A27 Epigenetic regulation in Ewing sarcoma. Sheetal Mitra, Children's Hospital Los Angeles, Los Angeles, California.

A28 Using LacZ reporter to investigate L1 expression and epigenetic regulation during mouse development. Wenfeng An, South Dakota State University, Brookings, SD.


A31 ZBTB46 is a novel oncogene that contributes to castration-resistant prostate cancer through activation of microRNA-1 DNA methylation. Yen-Nien Liu, Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

A32, PR10 Targeting CDK9 reactivates epigenetically silenced genes in cancer. Hanghang Zhang, Fels Institute for Cancer Research, Temple University School of Medicine, Philadelphia, PA.

A33 CTCs contribution in cancer therapy and progression. Nise Yamaguchi, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

A34 Epigenetic and transcriptional regulator gene mutations in relapsed acute myeloid leukemia. Samuli Eldfors, University of Helsinki, Helsinki, Finland.
Reversible LSD1 (KDM1A) inhibition with HCI2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners. Sumati Gupta, Huntsman Cancer Institute, Salt Lake City, Utah.

Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with SGI-110 and MS275. Yanrong Su, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania.